Grant supports partnerships between academia and industry to translate scientific discoveries into tools for disease research and care worldwide.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Renewal / Resubmission / Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal / Resubmission / Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal / Resubmission / Revision) | January 7, 2028 (Closing date)
Funding Amounts: Award ceiling: $499,000; direct-cost budgets limited to $499,000 annually for up to 5 years
Summary: NCI supports academic-industrial partnerships translating technologies into validated capabilities for disease research, diagnosis, treatment, and monitoring.
Key Information: Each partnership must include at least one academic and one industrial organization.
The National Cancer Institute (NCI) administers this R01 program to translate scientific discoveries and engineering developments into methods, assays, devices, and systems useful to end users. Interdisciplinary, multi-institutional teams should enhance, adapt, optimize, and validate technologies addressing targeted problems in risk assessment, detection, diagnosis, staging, treatment, or treatment monitoring. The program’s goals include better cancer screening, early detection, diagnosis, prognosis, treatment, and disease control.
Projects may serve preclinical research, clinical research, clinical care, or nonclinical research settings. Innovation means the likelihood of delivering a new capability to end users, rather than technical novelty alone. Clinical trials are optional and must test functionality or validate performance with translation as their primary motivation. Support extends through pre-commercial production, but excludes commercial production, basic research projects, and phase III clinical trials.